ArticleDiscover oncology2026
Integrated pan-cancer analysis and experimental validation reveal that syndecan-1 drives glioblastoma pathogenesis and associates with immune infiltration.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundsSyndecan-1 (SDC1) is a key transmembrane proteoglycan involved in cell adhesion and epithelial integrity. Although evidence links SDC1 to tumor progression, its pan-cancer functions and mechanistic roles are not fully understood.
methodsWe defined the multidimensional role of SDC1 across cancers by leveraging multi-platform genomic and clinical data. Our study characterized its associations with patient survival, molecular mechanisms, immune contexture, and therapeutic sensitivity. Initial observations in glioma subtypessuggested a pro-tumorigenic function. Consequently, this functional role in glioblastoma (GBM) was empirically validated through a combination of cellular-level assays and animal xenograft models.
resultsSDC1 expression was upregulated in numerous cancer types, correlating with poorer survival rates among patients. Receiver operating characteristic (ROC) analyses confirmed its robust diagnostic value across malignancies. Notably, a notable correlation was identified between SDC1 levels and key components within the tumor microenvironment, including CD4+/CD8 + T lymphocytes, cancer-associated fibroblasts (CAFs), and myeloid-derived suppressor cells (MDSCs). Functional assays revealed that SDC1 depletion markedly attenuated GBM cell proliferation and migration. Subsequently, the capacity for migration and tissue invasion was assessed using both experimental and animal model systems.
conclusionIntegrated bioinformatic and experimental analyses identify SDC1 as a pan-cancer biomarker with particular clinical significance in GBM. Its expression correlates with immune infiltration patterns, positioning SDC1 as a promising diagnostic and immunotherapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.